Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $1.48M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Galectin Therapeutics USD 1.48M 110K Jun/2024
Gilead Sciences USD 1.45B 326M Mar/2026
Immunic USD 3.45M 451K Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Merck USD 2.67B 180M Mar/2026